Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 3/20 | 0.41 |
| ▸ | CA2 | P00918 | 3/20 | 0.41 |
| ▸ | CA4 | P22748 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CA6 | P23280 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | NOS1 | P29475 | 1/20 | 0.38 |
| ▸ | NOS2 | P35228 | 1/20 | 0.38 |
| ▸ | HLCS | P50747 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9158941 | 1.00 | NPC1 (0.47) | NPC1RAB9ASMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL918856 | 1.00 | NPC1 (0.47) | NPC1RAB9ASMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL6659776 | 1.00 | NPC1 (0.47) | NPC1RAB9ASMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL4441775 | 1.00 | NPC1 (0.47) | NPC1RAB9ASMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL31632730 | 1.00 | NPC1 (0.47) | NPC1RAB9ASMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL25190402 | 1.00 | NPC1 (0.47) | NPC1RAB9ASMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL13725781 | 1.00 | NPC1 (0.47) | NPC1RAB9ASMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL4324112 | 1.00 | NPC1 (0.47) | NPC1RAB9ASMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL272161 | 0.98 | NPC1 (0.46) | NPC1RAB9ASMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL9319422 | 0.98 | NPC1 (0.46) | NPC1RAB9ASMN1; SMN2ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108929400-A | A kind of nickel catalyst system, high-performance polybutadiene and preparation method thereof | 北京化工大学 | 2018-12-04 | — | — | CN | claimed |
| US-20070184114-A1 | Formulation for topical non-invasive application in vivo | IDEA AG (DE) | 2007-08-09 | — | — | US | claimed |
| EP-1140021-B1 | IMPROVED FORMULATION FOR TOPICAL NON-INVASIVE APPLICATION IN VIVO | IDEA AG (DE) | 2004-08-04 | — | — | EP | claimed |
| JP-2002533379-A | — | — | 2002-10-08 | — | — | JP | claimed |
| US-20020064524-A1 | Formulation for topical non-invasive application in vivo | IDEA AG (DE) | 2002-05-30 | — | — | US | claimed |
| EP-1140021-A1 | IMPROVED FORMULATION FOR TOPICAL NON-INVASIVE APPLICATION IN VIVO | IDEA AG (DE) | 2001-10-10 | — | — | EP | claimed |
| WO-2000038653-A1 | IMPROVED FORMULATION FOR TOPICAL NON-INVASIVE APPLICATION IN VIVO | IDEA AG. (DE) | 2000-07-06 | — | — | WO | claimed |
| EP-0005196-A1 | Octylcyclohexane derivatives, their preparation and their use as perfuming agents | BASF Aktiengesellschaft (DE) | 1979-11-14 | — | — | EP | claimed |
| CN-114507123-B | Preparation method of 2-alkyl cyclohexanone homolog | 中国科学院大连化学物理研究所 | 2023-10-10 | — | — | CN | disclosed |
| CN-114507123-A | Preparation method of 2-alkyl cyclohexanone homologue | 中国科学院大连化学物理研究所 | 2022-05-17 | — | — | CN | disclosed |
| CN-114075101-A | Preparation method of 2-alkyl cyclohexanone compound | 中国科学院大连化学物理研究所 | 2022-02-22 | — | — | CN | disclosed |
| CN-108929400-A | A kind of nickel catalyst system, high-performance polybutadiene and preparation method thereof | 北京化工大学 | 2018-12-04 | — | — | CN | disclosed |
| EP-2485747-A1 | DNA-DIRECTED CUSTOMIZATION OF ANALGESIC COMPOUNDS AS A THERAPEUTIC MODALITY | Kenneth Blum, Inc. (US) | 2012-08-15 | — | — | EP | disclosed |
| EP-1178031-B1 | PROCESS FOR THE PREPARATION OF ORGANIC COMPOUNDS WITH MANGANESE CATALYSTS OR THE LIKE | DAICEL CHEM (JP) | 2012-02-01 | — | — | EP | disclosed |
| US-20020064524-A1 | Formulation for topical non-invasive application in vivo | IDEA AG (DE) | 2002-05-30 | — | — | US | disclosed |
| EP-1178031-A1 | PROCESS FOR THE PREPARATION OF ORGANIC COMPOUNDS WITH MANGANESE CATALYSTS OR THE LIKE | Daicel Chemical Industries, Ltd. (JP) | 2002-02-06 | — | — | EP | disclosed |
| EP-1140021-A1 | IMPROVED FORMULATION FOR TOPICAL NON-INVASIVE APPLICATION IN VIVO | IDEA AG (DE) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000038653-A1 | IMPROVED FORMULATION FOR TOPICAL NON-INVASIVE APPLICATION IN VIVO | IDEA AG. (DE) | 2000-07-06 | — | — | WO | disclosed |
| US-5451600-A | FOR TREATMENT OF INFLAMMATORY DISEASES AND TRAUMA INDUCED INFLAMMATION | HOFFMANN-LA ROCHE INC. (US) | 1995-09-19 | — | — | US | disclosed |
| EP-0005196-A1 | Octylcyclohexane derivatives, their preparation and their use as perfuming agents | BASF Aktiengesellschaft (DE) | 1979-11-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020064524-A1 | Formulation for topical non-invasive application in vivo | CUTA, LPO, GPX4 | NPC1 471/4885RAB9A 3821/4885SMN1; SMN2 3609/4885 |
| US-20070184114-A1 | Formulation for topical non-invasive application in vivo | GPX4, LPO, MMP8 | NPC1 264/4885RAB9A 2716/4885SMN1; SMN2 3444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.